Form 4: ANI Pharmaceuticals CEO Nikhil Lalwani Reports Stock Transaction
SEC Form 4 Filing
Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, reports disposition of shares for tax purposes related to vesting of restricted stock.
Summary
- On March 7, 2025, Nikhil Lalwani, the President & CEO of ANI Pharmaceuticals, reported a transaction involving common stock.
- 17,060 shares were disposed of to cover tax obligations at a price of $60.62 per share.
- Following the transaction, Lalwani directly owns 485,634 shares of ANI Pharmaceuticals.
- The transaction was related to the vesting of 33,352 shares of restricted stock.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing related to stock transactions by a company executive. The transaction itself (tax withholding) is a neutral event.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a standard tax withholding procedure related to the vesting of restricted stock, which is a common form of executive compensation.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, as it is a standard tax withholding procedure.
Key Dates
| Date | Description |
|---|---|
| 03/07/2025 | Date of stock transaction (disposal of shares). |
| 03/14/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.